Analysts raise target for Moderna stock to USD 118.42

Published on 10/13/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna reported USD 145.0 million revenue in Q2 2026. Moderna stock trades at EUR 192.59 on October 13, 2026, with USD 84.8 billion market value.

Key points in brief

TradingView reported that the average Moderna target rose from USD 116.84 to USD 118.42 on October 9, 2026.
Moderna reported USD 145.0 million in second-quarter 2026 revenue and a USD 782.0 million GAAP net loss.
The Lang & Schwarz quote was EUR 192.59 on October 13, 2026 at 11:10 a.m. CEST.
Moderna entered the Nasdaq-100 before market open on October 9, 2026.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) saw the average analyst target rise from USD 116.84 to USD 118.42 on October 9, 2026, as TradingView reported estimates from 19 analysts. The companys Lang & Schwarz quote was EUR 192.59 on October 13, 2026 at 11:10 a.m. CEST.

Target remains below the quote

The USD 118.42 average target sits in a different currency from the EUR 192.59 German quote, so the two values are not a direct price comparison. The same TradingView item said the consensus rating remained Hold across 27 analysts, with 6 Buys, 16 Holds and 5 Sells.

Markets Insider reported on October 7, 2026 that Morgan Stanley raised its target from USD 89.00 to USD 95.00 while retaining an Equal Weight rating. That target action shows how sharply analyst views differ from the recent share-price level.

Moderna results show the earnings gap

For the second quarter of 2026, Moderna reported USD 145.0 million in revenue, a USD 782.0 million GAAP net loss and a GAAP loss of USD 1.97 per diluted share, according to MarketBeat. Revenue was USD 145.0 million versus analyst expectations of USD 102.93 million, a quantified comparison that explains why the latest quarter cannot be reduced to the companys net loss.

Three milestones build the oncology case

On September 21, 2026, Moderna said three abstracts on intismeran autogene had been accepted for the ESMO Congress, including a Phase 3 melanoma study, according to Moderna. On September 30, 2026, the company announced one new chief operating officer role as it expanded its oncology organization, the same company release page shows. On October 9, 2026, Moderna became a Nasdaq-100 component after Nasdaq announced the change on October 1, 2026, replacing Warner Bros. Discovery, according to Nasdaq.

What does October 24 mean?

The next disclosed milestones are the October 24, 2026 ESMO Presidential Symposium presentation for the 1,137-patient INTerpath-001 Phase 3 melanoma study and a Moderna investor webcast later that day. The Des Moines Register reported that the study compares intismeran plus pembrolizumab with pembrolizumab alone. The October 25, 2026 pancreatic cancer poster is the second scheduled presentation listed in the same release.

Quote and company profile

Moderna was trading at EUR 192.59 at Lang & Schwarz on October 13, 2026 at 11:10 a.m. CEST. The finance quote showed a market capitalization of USD 84.8 billion as of October 12, 2026, while the primary Nasdaq range was USD 22.28 to USD 227.46 for the same quote snapshot. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.